蒋建东，1958年生，籍贯南京，药理学家，研究员，博士生导师。1988年复旦上海医学院获医学博士，1989年赴纽约大学西奈山医学院工作学习。1998年回国后在中国医学科学院北京协和医学院工作，先后任中国医学科学院医药生物技术所所长、药物研究所所长。2011年出任中国医学科学院药物研究院首任院长至今。现任中国医学科学院学部委员，中国工程院院士。

长期从事药物研究，包括抗感染、抗癌和抗代谢紊乱等。发现小檗碱是新机理降脂药物，成果已用于临床。研究多个抗癌药，绿原酸在二期临床。开展抗冠研究，阿兹夫定获中国药监局批准上市，另一个在美国三期临床。

1. Shu-Rong Ma#, Qian Tong#, Yuan Lin#, Li-Bin Pan#, Jie Fu#, Ran Peng, Xian-Feng Zhang, Zhen-Xiong Zhao, Yang Li, Jin-Bo Yu, Lin Cong, Pei Han, Zheng-Wei Zhang, Hang Yu, Yan Wang*, Jian-Dong Jiang*. Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota. Signal Transduct Target Ther. 2022 Jul 7;7(1):207. (IF=38.126)

2. Xiao-Lin Li, Jin-Jin Cui, Wen-Sheng Zheng, Jin-Lan Zhang, Rui Li, Xiao-Lei Ma, Miao Lin, Hui-Hui Guo, Cong Li, Xiao-You Yu, Peng Du, Li-Min Zhao, Shuwang He, Pei Lan, Jian-Dong Jiang*, Yongsheng Che*, Lu-Lu Wang*. Bicyclol Alleviates Atherosclerosis by Manipulating Gut Microbiota. Small. 2022 Mar;18(9):e2105021. (IF=15.153)

3. Ling Ren#, Xiao-Lei Ma#, Hong-Liang Wang#, Rui Li#, Jin-Jin Cui, Peng-Ju Yan, Ya-Nan Wang, Xiao-You Yu, Peng Du, Hao-Yang Yu, Hui-Hui Guo, Rou Tang, Yong-Sheng Che, Wen-Sheng Zheng*, Jian-Dong Jiang*, Lu-Lu Wang*. Prebiotic-like cyclodextrin assisted silybin on NAFLD through restoring liver and gut homeostasis. J Control Release. 2022 Aug;348:825-840. (IF=11.467)

4. Yan Wang#*, Qian Tong#, Shu-Rong Ma#, Zhen-Xiong Zhao#, Li-Bin Pan, Lin Cong, Pei Han, Ran Peng, Hang Yu, Yuan Lin, Tian-Le Gao, Jia-Wen Shou, Xiao-Yang Li, Xian-Feng Zhang, Zheng-Wei Zhang, Jie Fu, Bao-Ying Wen, Jin-Bo Yu, Xuetao Cao*, Jian-Dong Jiang*. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota. Signal Transduct Target Ther. 2021 Feb 24;6(1):77. (IF=38.126)

5. Jin-Lan Zhang#, Yu-Huan Li#, Lu-Lu Wang#, Hong-Qi Liu#, Shuai-Yao Lu#, Yong Liu, Ke Li, Bin Liu, Su-Yun Li, Feng-Min Shao, Kun Wang, Ning Sheng, Rui Li, Jin-Jin Cui, Pei-Chun Sun, Chun-Xia Ma, Bo Zhu, Zhe Wang, Yuan-Hao Wan, Shi-Shan Yu, Yongsheng Che, Chao-Yang Wang, Chen Wang, Qiangqian Zhang, Li-Min Zhao, Xiao-Zhong Peng*, Zhenshun Cheng*, Jun-Biao Chang*, Jian-Dong Jiang*. Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. Signal Transduct Target Ther. 2021 Dec 6;6(1):414. (IF=38.126)

6. Haiyan Yan#, Jing Sun#, Kun Wang#, Huiqiang Wang, Shuo Wu, Linlin Bao, Weiqing He, Dong Wang, Airu Zhu, Tian Zhang, Rongmei Gao, Biao Dong, Jianrui Li, Lu Yang, Ming Zhong, Qi Lv, Feifei Qin, Zhen Zhuang, Xiaofang Huang, Xinyi Yang, Yuhuan Li*, Yongsheng Che*, Jiandong Jiang*. Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2. Acta Pharm Sin B. 2021 Sep;11(9):2850-2858. (IF=14.911)

7. Wei-Jia Kong, Claudio Vernieri, Marco Foiani*, Jian-Dong Jiang*. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders. Pharmacol Ther. 2020 May;209:107496. (IF=13.4)

8. Hui-Hui Guo, Chen-Lin Feng, Wen-Xuan Zhang, Zhi-Gang Luo, Hong-Juan Zhang, Ting-Ting Zhang, Chen Ma, Yun Zhan, Rui Li, Song Wu, Zeper Abliz, Cong Li, Xiao-Lin Li, Xiao-Lei Ma, Lu-Lu Wang*, Wen-Sheng Zheng*, Yan-Xing Han*, Jian-Dong Jiang*. Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases. Nat Commun. 2019 Apr 30;10(1):1981. (IF=17.694)

9. Zong-Gen Peng, Zhi-Yun Zhao, Yan-Ping Li, Yu-Ping Wang, Lan-Hu Hao, Bo Fan, Yu-Huan Li, Yue-Ming Wang, Yong-Qiang Shan, Yan-Xing Han, Yan-Ping Zhu, Jian-Rui Li, Xue-Fu You, Zhuo-Rong Li*, Jian-Dong Jiang*. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology. 2011 Apr;53(4):1080-9. (IF=17.298)

10. Weijia Kong, Jing Wei, Parveen Abidi, Meihong Lin, Satoru Inaba, Cong Li, Yanling Wang, Zizheng Wang, Shuyi Si, Huaining Pan, Shukui Wang, Jingdan Wu, Yue Wang, Zhuorong Li, Jingwen Liu*, Jian-Dong Jiang*. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004 Dec;10(12):1344-51. (IF=87.241)